February 7, 2023

Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy

  • Meliksah Arslan,
  • Sarah Chalmers,
  • Kelly Rentfrow,
  • ...
  • Vicki Dean,
  • Mark E. Wylam,
  • Nadir Demirel
Published online: February 07, 2023

February 3, 2023

Short-term structural and functional changes after airway clearance therapy in cystic fibrosis

  • Michael E. West,
  • David R. Spielberg,
  • David J. Roach,
  • ...
  • Abdullah S. Bdaiwi,
  • Zackary I. Cleveland,
  • Jason C. Woods
Published online: February 03, 2023

February 2, 2023

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators

  • Carla Colombo,
  • Grant A Ramm,
  • Anders Lindblad,
  • ...
  • Rita Padoan,
  • Sahana Shankar,
  • Gianfranco Alicandro
Published online: February 02, 2023

January 28, 2023

The gut microbiome, short chain fatty acids, and related metabolites in cystic fibrosis patients with and without colonic adenomas

  • Brittany L. Baldwin-Hunter,
  • Felix D. Rozenberg,
  • Medini K. Annavajhala,
  • ...
  • Claire L. Keating,
  • Anne-Catrin Uhlemann,
  • Julian A. Abrams
Published online: January 28, 2023

January 27, 2023

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis

  • L.R. Caley,
  • C. Zagoya,
  • F. Duckstein,
  • ...
  • R.A. Floto,
  • J.G. Mainz,
  • D.G. Peckham
Published online: January 27, 2023
Open Access

Cost burden among the CF population in the United States: A focus on debt, food insecurity, housing and health services

  • Semret Seyoum,
  • Marsha Regenstein,
  • Marie Benoit,
  • ...
  • Anne Willis,
  • Kim Reno,
  • Cristen Clemm
Published online: January 27, 2023

January 24, 2023

Airway clearance therapy in the school environment: Retrospective analysis of a cohort of pediatric patients with cystic fibrosis

  • David J. Byrwa,
  • Geovanny F. Perez,
  • Christine M. Roach,
  • Sandra Prentice,
  • Danielle M. Goetz
Published online: January 24, 2023

January 23, 2023

Newborn screening for CF – The good, the bad and the ugly

  • Juerg Barben,
  • John Massie
Published online: January 23, 2023

January 22, 2023

Bariatric surgery in a patient with cystic fibrosis and diabetes: A case report

  • N.R.A. Bruijn,
  • M.A.E.M. Wagenmakers,
  • M. van Hoek,
  • J.A. Apers,
  • M.M. van der Eerden,
  • B. Özcan
Published online: January 22, 2023
Open Access

January 19, 2023

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre

  • Daniel H Tewkesbury,
  • Varinder Athwal,
  • Rowland J Bright-Thomas,
  • Andrew M Jones,
  • Peter J Barry
Published online: January 19, 2023

Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis

  • Carolin Steinack,
  • Matthias Ernst,
  • Felix Beuschlein,
  • ...
  • Macé M. Schuurmans,
  • Christoph Schmid,
  • Thomas Gaisl
Published online: January 19, 2023

January 18, 2023

Bone health outcomes in post-lung transplant patients with cystic fibrosis

  • Triet Vincent M. Tran,
  • Xilong Li,
  • Naim M. Maalouf
Published online: January 18, 2023

January 17, 2023

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

  • Normand E. Allaire,
  • Uta Griesenbach,
  • Batsheva Kerem,
  • John D. Lueck,
  • Noemie Stanleigh,
  • Yifat S. Oren
Published online: January 17, 2023

January 16, 2023

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®

  • Debanjali Purkayastha,
  • Kyla Agtarap,
  • Kristy Wong,
  • ...
  • Jannie Co,
  • Smita Pakhale,
  • Salmaan Kanji
Published online: January 16, 2023

January 10, 2023

January 9, 2023

Airway bacterial community composition in persons with advanced cystic fibrosis lung disease

  • Christina S. Thornton,
  • Lisa A. Carmody,
  • Linda M. Kalikin,
  • Kristopher Opron,
  • Lindsay J. Caverly,
  • John J. LiPuma
Published online: January 09, 2023

January 6, 2023

Cell signaling and regulation of CFTR expression in cystic fibrosis cells in the era of high efficiency modulator therapy

  • Alessandra Ghigo,
  • Chiara De Santi,
  • Merrill Hart,
  • Nilay Mitash,
  • Agnieszka Swiatecka-Urban
Published online: January 06, 2023

December 28, 2022

Prevalence, Risk Factors, and Sequelae of Asymptomatic Clostridioides difficile Colonization in Children with Cystic Fibrosis

  • Seth A. Reasoner,
  • Irtiqa F. Fazili,
  • Rachel Bernard,
  • ...
  • Kathryn M. Edwards,
  • Rebekah F. Brown,
  • Maribeth R. Nicholson
Published online: December 28, 2022

December 27, 2022

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS

  • Tim Lee,
  • Gregory S. Sawicki,
  • Josje Altenburg,
  • ...
  • Lisa J. McGarry,
  • Kate Van Brunt,
  • Rachel W. Linnemann
Published online: December 27, 2022
Open Access

Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial

  • Patrick A. Flume,
  • R. Scott Harris,
  • Hildegarde Paz-Diaz,
  • ...
  • Indrias Berhane,
  • Judy L. Shih,
  • Gregory Sawicki
Published online: December 27, 2022

December 26, 2022

Fundamental and translational research in Cystic Fibrosis – why we still need it

  • Carlos M. Farinha,
  • Jeffrey L. Brodsky,
  • Nicoletta Pedemonte
Published online: December 26, 2022
Open Access

December 25, 2022

Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis

  • Kang Dong,
  • Sung Moon Huh,
  • Grace Y Lam,
  • ...
  • Alessandro N. Franciosi,
  • Pearce G Wilcox,
  • Bradley S Quon
Published online: December 25, 2022

December 24, 2022

Impaired distal colonic pH in adults with cystic fibrosis

  • Dhiren Patel,
  • Stacy Mathews,
  • Vincent van Unen,
  • ...
  • Drucy Borowitz,
  • Daniel Gelfond,
  • Zachary M. Sellers
Published online: December 24, 2022

December 23, 2022

December 20, 2022

A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis

  • Erica A. Roesch,
  • Tracey L. Bonfield,
  • Hillard M. Lazarus,
  • ...
  • Elliot Dasenbrook,
  • Arnold I. Caplan,
  • James F. Chmiel
Published online: December 20, 2022

December 19, 2022

Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background

  • Valeria Tomati,
  • Stefano Costa,
  • Valeria Capurro,
  • ...
  • Carlo Castellani,
  • Maria Cristina Lucanto,
  • Nicoletta Pedemonte
Published online: December 19, 2022

December 16, 2022

Patient-derived cell models for personalized medicine approaches in cystic fibrosis

  • Anabela S. Ramalho,
  • Felice Amato,
  • Martina Gentzsch
Published online: December 16, 2022

High rates of anxiety detected in mothers of children with inconclusive cystic fibrosis screening results

  • Daniella K. Ginsburg,
  • Danieli B. Salinas,
  • Taylor M. Cosanella,
  • ...
  • Muhammed M. Saeed,
  • Thomas G. Keens,
  • Jeffrey I. Gold
Published online: December 16, 2022

December 14, 2022

Human papillomavirus prevalence, persistence and cervical dysplasia in females with cystic fibrosis

  • C. Rousset-Jablonski,
  • Y. Mekki,
  • A. Denis,
  • ...
  • I. Ray-Coquard,
  • F. Golfier,
  • I. Durieu
Published online: December 14, 2022

December 7, 2022

The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis

  • Renske van der Meer,
  • Erik B Wilms,
  • Margot N Eggermont,
  • Helena M Paalvast,
  • Richard C J M van Rossen,
  • Harry G M Heijerman
Published online: December 07, 2022

December 2, 2022

Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis

  • Alexandra P. Kass,
  • Traci M. Kazmerski,
  • Elana Bern,
  • ...
  • Katherine Barnico,
  • Tracy Richmond,
  • Gregory S. Sawicki
Published online: December 02, 2022

November 20, 2022

Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis

  • Eitan Kerem,
  • Annalisa Orenti,
  • Anna Zolin,
  • Luigi Annicchiarico,
  • Pavel Drevinek
  • on behalf of ECFSPR with the list of contributing authors
Published online: November 20, 2022

November 16, 2022

November 15, 2022

The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough

  • Iwona M. Pranke,
  • Jessica Varilh,
  • Aurélie Hatton,
  • ...
  • Magali Taulan,
  • Alexandre Hinzpeter,
  • Isabelle Sermet-Gaudelus
Published online: November 15, 2022

November 10, 2022

Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations

  • Galit Livnat,
  • Adi Dagan,
  • Moshe Heching,
  • ...
  • Michal Gur,
  • Malena Cohen-Cymberknoh,
  • Michal Shteinberg
Published online: November 10, 2022

European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance

  • Anne Munck,
  • Daria O Berger,
  • Kevin W Southern,
  • ...
  • Carlo Castellani,
  • Jürg Barben
  • For the European CF Society Neonatal Screening Working Group (ECFS NSWG)
Published online: November 10, 2022

November 9, 2022

Contemporary cystic fibrosis incidence rates in Canada and the United States

  • Anne L. Stephenson,
  • Sana Swaleh,
  • Jenna Sykes,
  • ...
  • Sameer Desai,
  • Elizabeth Cromwell,
  • Christopher H. Goss
Published online: November 09, 2022

November 5, 2022

Epidemiology and management of nontuberculous mycobacterial disease in people with cystic fibrosis, the Netherlands

  • Domenique Zomer,
  • Jakko van Ingen,
  • Regina Hofland
  • on behalf of the Dutch CF Registry Steering group
Published online: November 05, 2022
Open Access

October 30, 2022

Development of novel therapeutics for all individuals with CF (the future goes on)

  • Margarida D. Amaral,
  • Patrick T. Harrison
Published online: October 30, 2022

October 29, 2022

Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis

  • Baha Moshiree,
  • A. Jay Freeman,
  • Phuong T. Vu,
  • ...
  • Drucy Borowitz,
  • Meghana Sathe
  • On behalf of the GALAXY Study Group
Published online: October 29, 2022

October 27, 2022

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis

  • Kevin W. Southern,
  • Carlo Castellani,
  • Elise Lammertyn,
  • ...
  • Marieke Verkleij,
  • Michael D. Waller,
  • Alistair Duff
Published online: October 27, 2022
Open Access

October 21, 2022

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

  • Sarah Jane Schwarzenberg,
  • Phuong T. Vu,
  • Michelle Skalland,
  • ...
  • Steven M. Rowe,
  • Steven D. Freedman
  • for the Promise Study Group
Published online: October 21, 2022

October 14, 2022

The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study

  • Rebecca J. Birch,
  • Daniel Peckham,
  • Henry M. Wood,
  • ...
  • Genomics England Research Consortium,
  • Nicholas Burr,
  • Amy Downing
Published online: October 14, 2022
Open Access

October 7, 2022

Structure basis of CFTR folding, function and pharmacology

  • Tzyh-Chang Hwang,
  • Ineke Braakman,
  • Peter van der Sluijs,
  • Isabelle Callebaut
Published online: October 07, 2022

Restoring airway epithelial homeostasis in Cystic Fibrosis

  • Marco Cafora,
  • Marc Chanson,
  • Anna Pistocchi
Published online: October 07, 2022

October 6, 2022

Sexual and reproductive health experiences and care of adult women with cystic fibrosis

  • Traci M. Kazmerski,
  • Olivia M. Stransky,
  • Daniel R. Lavage,
  • ...
  • Joanne Billings,
  • Denis Hadjiliadis,
  • Raksha Jain
Published online: October 06, 2022
Advertisement